European regulators nod for Roche's Zelboraf

European Drug Regulators have approved the skin cancer drug, Zelboraf containing active ingredient Vemurafenib, for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma, which is a fatal form of skin cancer.

Roche, manufacturer of Zelboraf, has announced this on Monday.

From SayPeople,

Zelboraf can be used as a monotherapy for the treatment of adult patients, whose late stage skin cancer have spread to other parts of the body and become inoperable. It can be given as a twice daily pill.

Further Reading:
SayPeople